3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
4
Phase 1/2
2
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
53
Lymphoma
44
Lymphoma, Large B-Cell, Diffuse
35
Lymphoma, Follicular
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Lymphoma, Non-Hodgkin
22
Multiple Myeloma
19
Leukemia
17
Burkitt Lymphoma
13
Hodgkin Disease
12
Lymphoma, Mantle-Cell
10
Neoplasms
8
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, Large-Cell, Anaplastic
7
Neoplasms, Plasma Cell
6
Neoplasm Metastasis
6
Lymphoma, T-Cell, Peripheral
6
Recurrence
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pain
3
Lymphoma, B-Cell
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Myasthenia Gravis
2
Leukemia, Biphenotypic, Acute
2
Disease
2
Interventions
Doxorubicin
3
10-propargyl-10-deazaaminopterin
3
Vincristine
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Gemcitabine
2
Drug Therapy
2
Cyclophosphamide
2
Alemtuzumab
2
romidepsin
1
cc-486
1
belinostat
1
Vitamin B 12
1
Stem Cell Transplantation
1
Standard of Care
1
Specimen Handling
1
Prednisone
1
Practice Guidelines as Topic
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Hematopoietic Stem Cell Mobilization
1
Folic Acid
1
Etoposide
1
Cytarabine
1
Cladribine
1
Carmustine
1
Busulfan
1
Brentuximab Vedotin
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell
×
Prednisone
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA